Literature DB >> 3552702

The trometamol salt of fosfomycin: microbiological evaluation.

D Greenwood, S Coyle, J Andrew.   

Abstract

The spectrum of activity of fosfomycin and its pharmacological behaviour make it an attractive candidate for the oral treatment of uncomplicated urinary tract infection. Various factors affect the antibacterial activity so that results in different culture media vary widely. The highest activity was displayed in Eugonbroth and such results correlated well with those obtained in pooled human urine. The activity was enhanced in acid conditions such as commonly exist in infected urine. Glucose-6-phosphate potentiated the activity of fosfomycin against Escherichia coli and some other bacteria when tested in Eugonbroth (but less predictably in human urine) and the potentiating effect may be necessary in order to obtain therapeutically meaningful results in susceptibility tests. Experiments in an in vitro model of the treatment of bacterial cystitis (carried out in the absence of glucose-6-phosphate) indicated that both sensitive and 'resistant' strains of E. coli respond to concentrations of fosfomycin achievable by high-dose oral therapy with the trometamol salt. Resistance did not emerge in previously sensitive strains (or in one of the 2 'resistant' strains), providing a high peak level of antibiotic was achieved.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3552702     DOI: 10.1159/000472866

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  14 in total

1.  Prophylactic chemotherapy with fosfomycin trometamol versus placebo during transurethral prostatic resection.

Authors:  L Baert; I Billiet; J Vandepitte
Journal:  Infection       Date:  1990       Impact factor: 3.553

Review 2.  Fosfomycin: an old, new friend?

Authors:  M Popovic; D Steinort; S Pillai; C Joukhadar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-14       Impact factor: 3.267

3.  Comparison of the response of Escherichia coli to fosfomycin and fosmidomycin.

Authors:  Y Kanimoto; D Greenwood
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

4.  Activity of fosmidomycin in an in vitro model of the treatment of bacterial cystitis.

Authors:  Y Kanimoto; D Greenwood
Journal:  Infection       Date:  1987 Nov-Dec       Impact factor: 3.553

5.  Interpretive criteria and quality control parameters for determining bacterial susceptibility to fosfomycin tromethamine.

Authors:  A L Barry; M A Pfaller; P C Fuchs; F C Tenover; L B Reller; S D Allen; D J Hardy; E H Gerlach
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

6.  Fosfomycin trometamol: activity in vitro against urinary tract pathogens.

Authors:  D Greenwood
Journal:  Infection       Date:  1990       Impact factor: 3.553

7.  Prophylactic chemotherapy with fosfomycin trometamol during transurethral surgery and urological manoeuvres. Results of a multicentre study.

Authors:  F di Silverio; G Ferrone; L Carati
Journal:  Infection       Date:  1990       Impact factor: 3.553

8.  Fosfomycin trometamol versus ofloxacin/co-trimoxazole as single dose therapy of acute uncomplicated urinary tract infection in females: a multicentre study.

Authors:  K G Naber; U Thyroff-Friesinger
Journal:  Infection       Date:  1990       Impact factor: 3.553

9.  Fosfomycin trometamol: historical background and clinical development.

Authors:  G Gialdroni Grassi
Journal:  Infection       Date:  1990       Impact factor: 3.553

10.  Fosfomycin trometamol in a single dose versus norfloxacin for seven days in the treatment of uncomplicated urinary infections in general practice.

Authors:  J B Boerema; F T Willems
Journal:  Infection       Date:  1990       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.